313668-24-5

Basic information

• Product Name: tert-butyl (6AS,10AR)-2-(4-chloro-2-fluorophenyl)-4,5,7,8, 10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6AH)-carboxylate
• Synonyms: tert-butyl (6AS,10AR)-2-(4-chloro-2-fluorophenyl)-4,5,7,8, 10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6AH)-carboxylate
• CAS NO: 313668-24-5
• Molecular Weight: 428.934
• Mol File: 313668-24-5.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl (6AS,10AR)-2-(4-chloro-2-fluorophenyl)-4,5,7,8, 10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6AH)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (6AS,10AR)-2-(4-chloro-2-fluorophenyl)-4,5,7,8, 10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6AH)-carboxylate(313668-24-5)
• EPA Substance Registry System: tert-butyl (6AS,10AR)-2-(4-chloro-2-fluorophenyl)-4,5,7,8, 10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6AH)-carboxylate(313668-24-5)

Safety Data

• Hazardous Substances Data: 313668-24-5(Hazardous Substances Data)

Upstream product

• 160591-91-3 4-chloro-2-fluorophenylboronic acid 

Downstream Products

• 313668-26-7 (6AS,10AR)-2-(4-chloro-2-fluorophenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole 

Relevant articles and documents

Substituted heterocycle fused gamma-carbolines

The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

Substituted heterocycle fused gamma-carbolines

The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.